65 results about "Cancer marker" patented technology

The invention relates to the technical field of biosensors, in particular to a novel thin film material for a molecular diagnosis nascent biosensor, a thin film transistor and a preparation method and application of the novel thin film material and the thin film transistor. The thin film transistor is prepared from a novel thin film material, the thin film material covers the surface of a substrate of the transistor, and a source electrode and a drain electrode of the transistor are arranged between the substrate and a thin film in parallel. The concentration of the cancer marker is detected by monitoring the variable quantity of threshold voltage (Vth) in a transfer curve of the organic-inorganic hybrid thin film transistor, the responsivity and sensitivity to a disease marker are improved by optimizing a semiconductor material combination, efficient detection of the low-concentration cancer marker is realized, and the method has the characteristics of no label, rapidness, simplicity and convenience, and is suitable for popularization and application. The kit is suitable for early diagnosis of diseases.

The invention is suitable for the technical field of artificial intelligence, and particularly relates to a prediction method combining multi-relation hypergraph modeling and comparative learning, and the method comprises the steps: constructing a hypersubgraph containing an explicit and implicit regulation and control relation through a multi-relation view angle, the construction modes of the hypergraph comprise a data driving mode, a knowledge driving mode and a rule driving mode; performing feature learning on the constructed hyper-subgraphs through a hyper-graph convolution operator, and extracting high-order feature representations of nodes in different hyper-subgraphs; enhancing the consistency and distinguishing ability of node feature representation through comparative learning, and optimizing cross-subgraph feature representation; and fusing node feature representations of different hyper-graphs through an attention mechanism to generate a globally optimized node descriptor. The method provided by the invention not only improves the prediction accuracy, but also provides important theoretical support for mining potential cancer markers.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research, and therapy. In particular, provided herein are methods for diagnosis, prognosis and / or treatment of prostate cancer based on expression levels of cancer markers.

Provided for herein in several embodiments are anti-BCMA binding moieties. These anti-BCMA binding moieties may be used in BCMA-directed chimeric antigen receptors (CARs). Also disclosed herein are immune cell-based compositions comprising the anti-BCMA binding moieties and BCMA-directed CARs. In several embodiments, the immune-cell based compositions also target an additional tumor marker and / or an additional epitope of BCMA. In several embodiments, the BCMA-directed CAR is expressed in a Natural Killer cell. In several embodiments, combinations of BCMA-CAR-expressing NK cells are administered in conjunction with, for example CAR-expressing NK cells and / or CAR-expressing T cells that are directed to an additional cancer marker and / or an additional epitope of BCMA. Also provided for herein are methods and uses of the chimeric antigen receptors in immunotherapy.

The present application relates to the medical technical field, especially to the application of FYB1 gene as a marker in preparation of gastric cancer diagnosis or prognosis judging reagent. The present application research finds that FYB1 gene is highly expressed in gastric cancer tissue and negatively correlated with the prognosis of patients, and can be used as a gastric cancer marker for gastric cancer detection and efficacy evaluation. In addition, FYB1 is positively correlated with the expression of Treg cell marker FOXP3 and co-localized in tissues, suggesting that FYB1 may promote gastric cancer tumor immune escape; the expression of FYB1 gene can significantly inhibit the proliferation, migration and invasion ability of gastric cancer cells, and inhibit tumor growth, indicating that FYB1 gene can be used as a gastric cancer treatment target and play an important role in the treatment of gastric cancer patients.

The invention provides a plasma exosome mRNA biomarker and application thereof in construction of a gastric cancer diagnosis model, and relates to the technical field of biological medicine. The plasma exosome mRNA MORC3 is found to be remarkably enriched in the plasma of a gastric cancer patient for the first time, and it is indicated that the plasma exosome mRNA MORC3 is expected to serve as a biomarker for gastric cancer diagnosis and a target gene for gastric cancer treatment. A diagnosis model and a corresponding diagnosis system for gastric cancer are constructed by taking plasma exosome mRNA MORC3 as a target marker, and the diagnosis model provided by the invention shows relatively high sensitivity and specificity in the aspect of distinguishing gastric cancer patients from healthy people, shows relatively good diagnosis efficiency, can effectively identify the gastric cancer patients, and has a good application prospect. And an effective auxiliary tool is provided for clinical diagnosis. The invention provides a new choice for the molecular marker for gastric cancer diagnosis, overcomes the defect of low sensitivity when the existing cancer marker is used in the gastric cancer section, and provides a new method for early screening and diagnosis of gastric cancer.

The present invention discloses a kit for detecting gastric cancer markers and its application, which belongs to the field of in vitro diagnosis. The kit for detecting gastric cancer markers comprises an enzyme label plate coated with a capture antibody, an HRP-labeled antibody working solution, an antigen standard, a washing solution, a color developing solution and a stop solution; the capture antibody G1EA and the HRP-labeled antibody G2EA are both antibodies that specifically bind to the GRK3 antigen. The kit for detecting gastric cancer markers of the present invention has strong specificity, can specifically detect the GRK3 protein content in serum, and is used as an auxiliary diagnostic method for gastric cancer with high expression of GRK3 protein, and has good stability and good application prospects.

The invention relates to the technical field of biosensing, and particularly discloses a sialic acid (SA) concentration detection method based on a micro-cantilever sensor. Comprising the following steps: (1) preparing a monocrystalline silicon micro-cantilever sensor, and modifying 4-mercaptophenylboronic acid (4-MPBA) on the surface of a cantilever through an Au-S bond to serve as an SA acceptor molecule; (2) constructing an optical lever detection system, and monitoring the deformation of the cantilever beam in real time through laser reflection displacement; (3) enabling a sample to be detected to be in contact with the modified sensor, and triggering surface quality change of a cantilever beam by utilizing specific binding of 4-MPBA and SA, so as to cause resonant frequency deviation; and (4) establishing a relation model of the frequency value f and the SA concentration through a regression algorithm to realize quantitative detection of the SA concentration. Through a label-free dynamic detection mechanism, an enzyme labeling step required by a traditional ELISA method is avoided, and a rapid and low-cost solution is provided for cancer marker screening.

The present invention belongs to the field of biomedicine technology, and specifically relates to an ELISA kit for detecting gastric cancer markers and its application. The kit includes an enzyme labeling plate coated with a capture antibody and an HRP-labeled antibody working solution; the heavy chain amino acid sequence of the capture antibody RAD54L-1 is shown in SEQ ID NO.1, and the light chain amino acid sequence is shown in SEQ ID NO.2; the heavy chain amino acid sequence of the HRP-labeled antibody RAD54L-2 is shown in SEQ ID NO.3, and the light chain amino acid sequence is shown in SEQ ID NO.4. The ELISA kit for detecting gastric cancer markers of the present invention has strong specificity, can specifically detect the RAD54L protein content in serum, and is used as an auxiliary diagnostic method for gastric cancer with high expression of RAD54L protein, and has good stability and good application prospects.

The invention provides a rapid detection reagent for a gastric cancer marker in saliva as well as a preparation method and application of the rapid detection reagent. The detection reagent comprises a composite material shell structure and a signal molecule 3-MPBA, wherein the composite material shell structure is formed by coating silver nanoparticles on cobalt-polyphenol nanospheres. The method comprises the following steps: firstly, taking L-TA as a polymeric ligand, coordinating with Co ions to form chiral nanoparticles, and triggering an interface redox reaction and successfully loading AgNPs by utilizing the unique redox characteristic of catechol / galloyl in the L-TA; due to the formation of Ag-Co bimetallic double active centers, ionization of boron hydroxyl under neutral pH is accelerated by electron transfer behavior, and hydroxyl alcohol esterification reaction is carried out among D-Ala, D-Pro and 3-MPBA. On the basis, the enhancement of a Raman signal can be realized, so that the D-Pro / Ala in a saliva sample can be measured by utilizing the bimetallic heterostructure nano composite material, and the purposes of high sensitivity and selectivity are achieved.

The invention relates to the technical field of Raman spectrum analysis and machine learning, in particular to a serum Raman spectrum noninvasive pathological detection device. Comprising an acquisition module for acquiring a surface enhanced Raman spectrum of a serum sample to be detected to obtain spectral data to be analyzed; the screening module is used for obtaining qualified spectral data based on a wavelet transform signal-to-noise ratio energy criterion; the storage module is used for storing the data to a database; the calculation module is used for reading qualified spectral data to obtain a characteristic signal; and the reasoning module is used for inputting the characteristic signal into a pre-trained model, outputting a reasoning process and a pathological judgment result, positioning a key interval and a characteristic peak corresponding to the result based on interpretability analysis, and outputting corresponding biomolecule attribution information. Therefore, the problems that in the prior art, spectrum quality is difficult to control, complex spectrums are difficult to analyze, and a model decision-making mechanism and interpretability are insufficient are solved, potential cancer marker characteristics in the spectrums are effectively mined, and efficient and credible early cancer accurate diagnosis is assisted to be achieved.

The present invention provides a terahertz metamaterial biosensor and its application. Based on micro-nano processing technology, the present invention attaches a subwavelength metal resonant ring array on a dielectric substrate to form a metamaterial sensor. The subwavelength metal resonant ring is composed of two fan-shaped resonant rings with an angle of 60° to form a structure similar to the shape of an "8", and two gaps are formed at the upper and lower ends of the structure to generate annular dipole resonance, which can achieve high quality factor and high sensitivity sensing in the terahertz band. Colloidal gold nanoparticles functionalized by biomodification technology not only enhance the sensing performance of the metamaterial biosensor and significantly reduce the detection limit, but also achieve specific recognition of the cancer marker carcinoembryonic antigen. The metamaterial sensor combined with functionalized gold nanoparticles proposed by the present invention has excellent high quality factor sensing performance, can achieve high sensitivity and specific detection of carcinoembryonic antigen, the method is simple and effective, and has broad application prospects.

The disclosure relates to an (isolated) antibody (or antibody fragment / antigen binding fragment thereof) binding to (human) HMGI-C (anti-HMGI-C-Antibody) as well the nucleic acid encoding such an antibody or host cells comprising these or pharmaceutical composition comprising the antibody. Preferred antibodies are binding to the epitopes of SEQ. ID NOs. 32, 33 or 34, especially the (monoclonal) antibodies that comprise in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 4; in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 14; or in its heavy chain variable region (VH) the amino acid CDR sequence CDR3 of SEQ ID NO. 24. Especially preferred are also the (monoclonal) antibodies that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 1 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 6; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 11 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 16; that comprise a heavy chain variable region (VH) having amino acid sequence of SEQ ID NO. 21 and a light chain variable region (VL) having amino acid sequence of SEQ ID NO. 26. In addition, the disclosure relates to a lateral flow device for the detection of HMGI-C, especially the HMGI-C released during an event leading to an acute aortic syndrome / acute aortic dissection (AAS / AAD) or in relation to cancer in a sample of bodily fluid of a human / patient using an antibody of the disclosure or to the use of the antibody for the treatment of cancer or for cancer prevention by early detection of HMGI-C as a marker for cancer.

The invention discloses an identification method of a single cell ecDNA cloning trajectory. Potential tumor markers in single cell ATAC data are identified based on ecDNA cloning characteristics. The cancer marker is recognized through the ecDNA, tumor cells can be sensitively recognized, and early diagnosis can be carried out; the copy number, the structure and the distribution of the ecDNA often have great heterogeneity in tumor cells. Different types of ecDNA clones may be carried among different tumor cell populations, so that the evolution trajectory of tumors and the diversity of the cell populations can be disclosed; according to the present invention, the gene structure change of the tumor cell population in different stages can be revealed by researching the clone trajectory of the ecDNA so as to provide the potential marker for the early screening and monitoring of cancers.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and / or treating prostate cancer based on expression levels of cancer markers.

The present invention relates to the application of SOX13 as a gastric cancer biomarker. By constructing ferroptosis-resistant strains, the present invention uses a microarray to screen out SOX13 as an important regulatory molecule for gastric cancer ferroptosis sensitivity, and discovers that the anti-influenza drug zanamivir can specifically target the SOX13 protein. The present invention effectively verifies that the SOX13 gene is involved in the regulation of gastric cancer ferroptosis sensitivity, providing theoretical data for the ferroptosis sensitivity and chemosensitivity of gastric cancer cells. In addition, zanamivir can specifically target the SOX13 protein and reverse gastric cancer ferroptosis resistance, providing a theoretical basis for the treatment of ferroptosis resistance and chemoresistance of gastric cancer cells.

Provided herein are kits and methods useful for cancer diagnosis, prognosis, research and therapy. In particular, provided herein are methods of diagnosing, prognosing, and / or treating prostate cancer based on expression levels of cancer markers.

The application provides a plasma exosome mRNA biomarker and application thereof in construction of a gastric cancer diagnosis model, and relates to the technical field of biological medicine.The application first discovers that plasma exosome mRNA MORC3 is significantly enriched in plasma of gastric cancer patients, indicating that the plasma exosome mRNA MORC3 is expected to be used as a biomarker for gastric cancer diagnosis and as a target gene for treatment of gastric cancer.We take the plasma exosome mRNA MORC3 as a target marker to construct a diagnosis model and a corresponding diagnosis system for gastric cancer.The diagnosis model provided by the application shows high sensitivity and specificity in distinguishing gastric cancer patients from healthy people, displays good diagnosis efficiency, and can effectively identify gastric cancer patients, thereby providing an effective auxiliary tool for clinical diagnosis.The application provides a new choice for a molecular marker for gastric cancer diagnosis, overcomes the low sensitivity of existing cancer markers when used for gastric cancer diagnosis, and provides a new method for early screening and diagnosis of gastric cancer.

The invention belongs to the technical field of biological medicines, and particularly relates to an ELISA (enzyme-linked immuno sorbent assay) kit for detecting gastric cancer markers and application of the ELISA kit. The kit comprises an elisa plate coated with a captured antibody and an HRP labeled antibody working solution, the heavy chain amino acid sequence of the capture antibody RAD54L-1 is as shown in SEQ ID NO.1, and the light chain amino acid sequence of the capture antibody RAD54L-1 is as shown in SEQ ID NO.2; the heavy chain amino acid sequence of the HRP labeled antibody RAD54L-2 is shown as SEQ ID NO.3, and the light chain amino acid sequence of the HRP labeled antibody RAD54L-2 is shown as SEQ ID NO.4. The ELISA kit for detecting the gastric cancer marker is high in specificity, can specifically detect the content of RAD54L protein in serum, serves as a gastric cancer auxiliary diagnosis means for highly expressing RAD54L protein, and is good in stability and good in application prospect.

Provided herein are compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, provided herein are methods of treating basal-like breast cancer based on expression levels of a panel of cancer markers.

The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to ncRNAs as diagnostic markers and clinical targets for prostate, lung, breast and pancreatic cancer.

Provided herein are kits and methods useful for cancer screening, diagnosis, research and therapy. In particular, provided herein are methods of screening, diagnosing, and / or treating prostate cancer based on expression levels of cancer markers.

The invention relates to the technical field of biological detection, and provides an integrated electrochemical detection device for stomach cancer postoperative MRD auxiliary detection as well as a preparation method and application of the integrated electrochemical detection device. The core of the device is that a functional nanofiber sensing interface layer and a preset freeze-drying reagent layer are sequentially constructed on a working area of a screen printing electrode (SPE). Wherein the sensing interface layer fixes an anti-CD63 capture antibody through an electrostatic spinning polyacrylic acid (PAA) nanofiber membrane, and is used for efficiently enriching plasma exosomes; and the freeze-drying reagent layer comprises a detection antibody of a targeted gastric cancer marker Claudin18.2, a streptavidin-horse radish peroxidase signal reporting system and a freeze-drying protective agent. According to the invention, the unification of high precision of detection and extremely simplified operation is realized through a unique'mask protection 'process and a'reagent freeze-drying integration' technology. The device has the outstanding advantages of high detection sensitivity, good specificity, convenience in operation, good accuracy and the like.

The present application discloses a method for analyzing pathological image data based on artificial intelligence, and the present application belongs to the field of artificial intelligence. The method includes: performing cancer type annotation and multi-label feature annotation on each pathological image in the first pathological image dataset, and updating the first pathological image dataset; creating a multi-task learning model; creating a joint loss function; training the multi-task learning model according to the joint loss function and the updated first pathological image dataset, and if the multi-task learning model reaches a preset model determination criterion, the training is completed; identifying the type information, pathological features, and cancer markers of the pathological image according to the multi-task learning model, determining a diagnosis result based on the type information, pathological features, and cancer markers, and sending it to the intelligent terminal device of the doctor. This solution enables doctors to obtain more comprehensive diagnostic information from one model, reduces the time for multiple diagnoses, and improves the response speed and diagnostic efficiency of medical services.

The invention belongs to the technical field of biology, particularly relates to application of a colon cancer marker and a colon cancer diagnosis kit, and provides application of a reagent for detecting the expression quantity of JOSD1 in preparation of a colon cancer diagnosis product, application of a reagent for inhibiting the expression quantity of JOSD1 in preparation of a colon cancer treatment product and application of a reagent for inhibiting the expression quantity of JOSD1 in preparation of a colon cancer diagnosis product. According to the present invention, the JOSD1 is determined to influence the growth of the Hippo signal and the colon cancer, and the forward feedback between the Hippo pathway and the JOSD1 is determined so as to drive the progress of the colorectal cancer, the JOSD1 is determined to influence the growth of the Hippo signal and the colon cancer, and the forward feedback between the Hippo pathway and the JOSD1 is determined so as to drive the progress of the colorectal cancer.

Recently, aptamers have been considered in cancer diagnosis and treatment applications by binding to various bioreceptor molecules. Given that the p53 protein is responsible for approximately 50% of cancers, its identification is promising, but so far, no aptamer DNA sequence has been designed for the p53 protein and aptamer-based sensor. The purpose of this invention is to develop a nanoparticle-based aptamer sensor and use the p53 bioreceptor for cancer diagnosis with high sensitivity in the shortest time. In this regard, a DNA aptamer-based sensor was used on a glassy carbon electrode coated with gold nanoparticles / graphene oxide / conductive polymer . This sensor was created by the gold nanoparticles / aptamer-toluidine blue enhancer. The results obtained under optimal conditions of electrochemical investigation using amperometry indicated a detection limit of 0.29 picograms / mL in phosphate buffer and 0.341 picograms / mL in human blood plasma and a linear range of 1 to 300 picograms / mL for the sensor. This invention demonstrates the excellent and controllable performance of a modified carbon electrode to create a suitable sensor for detecting the cancer marker p53 protein.

This disclosure relates to nanoparticles coated with fusion proteins comprising a domain that binds a cancer marker and a domain comprising a toxic polypeptide. In certain embodiments, the targeted cancer marker is urokinase plasminogen activator receptor (uPAR) insulin-like growth factor 1 receptor (IGF1R), EGFR, HER2, and / or other member of the ErbB family of receptors. In certain embodiments, the molecule that binds a cancer marker is an amino terminal fragment of uPA or variant capable of binding uPAR and / or IGF1 or variant capable of binding IGF1R. In certain embodiments, the toxic polypeptide is a bacterial exotoxin.

The invention relates to the technical field of medicines, in particular to application of an FYB1 gene as a marker in preparation of a reagent for gastric cancer diagnosis or prognosis. Researches find that the FYB1 gene is highly expressed in gastric cancer tissues and is in negative correlation with prognosis of patients, and the FYB1 gene can be used as a gastric cancer marker to be applied to gastric cancer detection and curative effect evaluation. In addition, the expression of the FYB1 and the expression of a Treg cell marker FOXP3 are in positive correlation and co-localization exists in tissues, which prompts that the FYB1 can promote the immune escape of the gastric cancer tumor; by inhibiting the expression of the FYB1 gene, the proliferation, migration and invasion capabilities of gastric cancer cells can be remarkably inhibited, and the tumor growth is inhibited, so that the FYB1 gene can be used as a gastric cancer treatment target and plays an important role in the treatment of gastric cancer patients.

The invention is applicable to the technical field of biomedicine, and provides a serum protein marker, a kit and a detection method for early screening and diagnosis of pan cancer, the serum protein marker is RNASE4 protein, and the amino acid sequence of the serum protein marker is as shown in SEQ ID NO.1. The application finds that the serum concentration of the RNASE4 protein is remarkably related to various cancers for the first time, the RNASE4 protein can be used as an ideal marker for diagnosis of the pan-cancer, and the RNASE4 protein is provided as the pan-cancer marker, the matched kit and the detection method, so that the problems that the existing CA type marker is low in accuracy and sensitivity and easy to interfere are solved; high-specificity and high-sensitivity non-invasive early screening of intestinal cancer, pancreatic cancer, bladder cancer, breast cancer and ovarian cancer is achieved, the area under an ROC curve is larger than or equal to 0.85, detection operation is easy and convenient, and stability is good.

Provided is a technique for detecting, with high sensitivity, a specific protein that can be used as a cancer marker. More specifically, the present invention provides a method and the like for detecting CEACAM1, the method comprising: (1) a step for modifying CEACAM1 in a sample containing CEACAM1 to produce modified CEACAM1; and (2) a step for measuring and detecting CEACAM1 by a sandwich method using both a capture antibody having the ability to recognize modified CEACAM1 and a labeled antibody.